{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:13:44Z","timestamp":1786990424642,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005107","name":"Ashland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijbiomac.2025.146288","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:51:27Z","timestamp":1753372287000},"page":"146288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P1","title":["In vitro, in vivo and in silico assessment of bioresorbable PLGA-PEG-PLGA based thermosensitive hydrogel mediated 30-days delivery of Lurasidone HCl for schizophrenia"],"prefix":"10.1016","volume":"321","author":[{"given":"Bankar Anup","family":"Ramprasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyashri","family":"Atre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Chaurasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.146288_bb0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0015","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0020","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/pharmaceutics17060750","article-title":"Phase-inversion in situ systems: problems and prospects of biomedical application","volume":"17","author":"Bakhrushina","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of Lurasidone, a novel antipsychotic agent with potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0030","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/00185787221139421","article-title":"In vitro assessment of compounded Lurasidone suspensions for enteral feeding tubes","volume":"58","author":"Wojcinski","year":"2023","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.powtec.2017.02.038","article-title":"Enhanced oral bioavailability and diminished food effect of lurasidone hydrochloride nanosuspensions prepared by facile nanoprecipitation based on dilution","volume":"312","author":"Yu","year":"2017","journal-title":"Powder Technol."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0040","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1517\/14656566.2015.1058780","article-title":"Lurasidone in the treatment of schizophrenia: a critical evaluation","volume":"16","author":"Bruijnzeel","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0045","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.2338","article-title":"Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies","volume":"28","author":"Preskorn","year":"2013","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0050","series-title":"Center for Drug Evaluation and Research Tertiary Pharmacology\/Toxicology Review","author":"Brown","year":"2009"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/TCRM.S12701","article-title":"Clinical potential of lurasidone in the management of schizophrenia","author":"Samalin","year":"2011","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40120-019-0138-z","article-title":"Practical guidance on the use of Lurasidone for the treatment of adults with schizophrenia","volume":"8","author":"Javed","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0065","series-title":"A Kind of Drug Solution Containing Lurasidone HCl and Preparation Method Thereof, CN107320444A","author":"Xiao","year":"2016"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/088740341305805s02","article-title":"Long-acting injectable antipsychotics: evidence of effectiveness and use, the","volume":"58","author":"Manchanda","year":"2013","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.polymer.2020.123216","article-title":"Insights in the rheological properties of PLGA-PEG-PLGA aqueous dispersions: structural properties and temperature-dependent behaviour","volume":"213","author":"Cespi","year":"2021","journal-title":"Polymer (Guildf.)"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0168-3659(01)00276-0","article-title":"Biodegradable block copolymers for delivery of proteins and water-insoluble drugs","volume":"72","author":"Zentner","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0085","doi-asserted-by":"crossref","first-page":"17531","DOI":"10.1021\/acsomega.0c02009","article-title":"In situ forming injectable thermoresponsive hydrogels for controlled delivery of biomacromolecules","volume":"5","author":"Dutta","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0090","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1039\/C6TB02158A","article-title":"Modified PLGA\u2013PEG\u2013PLGA thermosensitive hydrogels with suitable thermosensitivity and properties for use in a drug delivery system","volume":"5","author":"Wang","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0095","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1007\/s13346-022-01161-2","article-title":"Enhancing the function of PLGA-collagen scaffold by incorporating TGF-\u03b21-loaded PLGA-PEG-PLGA nanoparticles for cartilage tissue engineering using human dental pulp stem cells","volume":"12","author":"Ghandforoushan","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041229","article-title":"Injectable in-situ forming depot based on PLGA and PLGA-PEG-PLGA for sustained-release of risperidone: in vitro evaluation and pharmacokinetics in rabbits","volume":"15","author":"Rezaeian Shiadeh","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106691","article-title":"Enhancement of the solubility and oral bioavailability of altrenogest through complexation with hydroxypropyl-\u03b2-cyclodextrin","volume":"194","author":"Chen","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0110","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2147\/IJN.S28481","article-title":"Role of hydroxypropyl-\u03b2-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery","volume":"7","author":"Vega","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/gels10100649","article-title":"Dual-self-crosslinking effect of alginate-Di-aldehyde with natural and synthetic co-polymers as injectable in situ-forming biodegradable hydrogel","volume":"10","author":"Begum","year":"2024","journal-title":"Gels"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0120","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.pharma.2024.10.008","article-title":"Advanced stability-indicating RP-HPLC method for the quantification of lurasidone hydrochloride in bulk and PLGA-based in situ implant formulation","volume":"83","author":"Ramprasad","year":"2025","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0125","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1208\/s12249-012-9781-8","article-title":"Preparation and investigation of sustained drug delivery systems using an injectable, thermosensitive, in situ forming hydrogel composed of PLGA\u2013PEG\u2013PLGA","volume":"13","author":"Khodaverdi","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123794","article-title":"Understanding the impact of formulation design on microstructure and drug release from porous microparticle-based tretinoin topical gels","volume":"653","author":"Elfakhri","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jcis.2013.02.030","article-title":"A comparative study of submicron particle sizing platforms: accuracy, precision and resolution analysis of polydisperse particle size distributions","volume":"405","author":"Anderson","year":"2013","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0140","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/jbm.a.34800","article-title":"Thermoresponsive biodegradable PEG-PCL-PEG based injectable hydrogel for pulsatile insulin delivery","volume":"102","author":"Payyappilly","year":"2014","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0145","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s10973-013-3166-4","article-title":"Thermal transitions of gelatin evaluated using DSC sample pans of various seal integrities","volume":"114","author":"Mukherjee","year":"2013","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0150","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1039\/c2bm00159d","article-title":"The thermogelling PLGA\u2013PEG\u2013PLGA block copolymer as a sustained release matrix of doxorubicin","volume":"1","author":"Yu","year":"2013","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0155","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline Stability Testing of New Drug Substances and Products Q1A(R2)","author":"ICH Q1A(R2)","year":"2003"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0160","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.msec.2017.03.065","article-title":"3-month parenteral PLGA microsphere formulations of risperidone: fabrication, characterization and neuropharmacological assessments","volume":"75","author":"Chaurasia","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0165","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpharm.2006.09.025","article-title":"Curcumin\u2013phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats","volume":"330","author":"Maiti","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.nano.2008.12.003","article-title":"PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation","volume":"5","author":"Muthu","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00596","article-title":"The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use","volume":"11","author":"Yunusa","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0180","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.clinthera.2015.11.001","article-title":"Pharmacokinetics and tolerability of lurasidone in children and adolescents with psychiatric disorders","volume":"37","author":"Findling","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0185","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","article-title":"Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature","volume":"56","author":"Greenberg","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/2230-973X.153390","article-title":"Solubility enhancement studies on lurasidone hydrochloride using mixed hydrotropy","volume":"5","author":"Madan","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.carbpol.2014.10.070","article-title":"Characterization of hydroxypropyl-\u03b2-cyclodextrins with different substitution patterns via FTIR, GC\u2013MS, and TG\u2013DTA","volume":"118","author":"Yuan","year":"2015","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0200","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s12247-020-09480-y","article-title":"Optimization and in vitro evaluation of injectable sustained-release of levothyroxine using PLGA-PEG-PLGA","volume":"16","author":"Kamali","year":"2021","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0205","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/bdd.2252","article-title":"Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder","volume":"41","author":"Pardhi","year":"2020","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0210","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.xphs.2022.03.021","article-title":"Liquiritin-hydroxypropyl-beta-cyclodextrin inclusion complex: preparation, characterization, bioavailability and antitumor activity evaluation","volume":"111","author":"Wang","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0215","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/mabi.200300037","article-title":"Supramolecular hydrogel formation based on inclusion complexation between poly(ethylene glycol)-modified chitosan and \u03b1-Cyclodextrin","volume":"4","author":"Huh","year":"2004","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(98)00052-0","article-title":"Mechanisms of drug release from cyclodextrin complexes","volume":"36","author":"Stella","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0225","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"Costa","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0230","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/jps.2600521210","article-title":"Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices","volume":"52","author":"Higuchi","year":"1963","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0235","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/21691401.2018.1548470","article-title":"Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer","volume":"47","author":"Cao","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0014-2999(78)90251-0","article-title":"Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity","volume":"50","author":"Costall","year":"1978","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.146288_bb0245","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1037\/0735-7044.102.5.748","article-title":"The catalepsy test: its ups and downs","volume":"102","author":"Sanberg","year":"1988","journal-title":"Behav. Neurosci."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181302506845X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181302506845X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T16:19:23Z","timestamp":1755274763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014181302506845X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":49,"alternative-id":["S014181302506845X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.146288","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro, in vivo and in silico assessment of bioresorbable PLGA-PEG-PLGA based thermosensitive hydrogel mediated 30-days delivery of Lurasidone HCl for schizophrenia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.146288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"146288"}}